(Figure 2D) Altogether our phenotypic analysis of a preclinical model of highly aggressive, poorly immunogenic HNSCC tumors provide evidence that targeting PI3Kγ and PD-L1 signaling pathways could potentially enhance therapeutic efficacy against HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.